OBJECTIVE: LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal-based tablet enriched with the recommended daily doses of @entity2221 . The present study was undertaken to investigate possible prevention of recurrent @entity3305 (RHL) during 4 months' daily intake of LV. DESIGN: Placebo-controlled, double-blind, randomised, clinical trial. SUBJECTS: Fifty-two @entity1 with a minimum of 4 yearly @entity1733 episodes. METHODS: The @entity1 were given either LV or placebo for 4 months and followed-up for another 4 months. The number, duration and maximal size of lesions were assessed. RESULTS: Twenty-seven @entity1 (Group A) received LV and 25 @entity1 placebo (Group B). There were no statistically significant differences between Group A and Group B with respect to number, duration and size of lesions. Within Group A, however, there was a decrease in all three parameters after 2 months' intake of LV (P < 0.05). The decrease in the number of @entity1733 episodes in Group A lasted during the entire follow-up period (P < 0.05). At the end of the medication period, significantly more @entity1 in Group A than in Group B assessed the number and duration of recurrences to be reduced compared with before the trial (P < 0.05). CONCLUSION: LV was not superior to placebo in the prevention of RHL although subjective assessment was in favour of LV, and the LV group had less episodes after 2 months on the tablets.

LongoVital and XXXX : a randomised, double-blind, placebo-controlled study.

@entity3305 :: ('MESH:D006560', 'Disease') :: ['herpes labialis'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1733 :: ('MESH:C538324', 'Disease') :: ['HL'] @entity2221 :: ('CHEBI:33229', 'Chemical') :: ['vitamins']
@entity3305 :: (MESH:D006560,Disease) :: ['herpes labialis']
